Truist on Abivax (ABVX): 'We continue to see a robust opportunity'

March 24, 2026 9:01 AM

Truist Securities analyst Greg Renza reiterated a Buy rating and $140.00 price target on Abivax (NASDAQ: ABVX).The analyst commented: "Recent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found